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Abstract The oral sphingosine 1-phosphate receptor
(S1PR) modulator fingolimod functionally antagonizes
S1PR hereby blocking lymphocyte egress from secondary
lymphoid organs to the peripheral blood circulation. This
results in a reduction in peripheral lymphocyte counts,
including potentially encephalitogenic T cells. In patients
with relapsing multiple sclerosis fingolimod has been
shown to be an effective treatment. In phase 2 and phase
3 studies fingolimod-treated patients had reduced disease
activity clinically and in MRI. Although severe infectious
complications occurred in single cases treated with fingo-
limod, the frequency of overall infections was comparable
in fingolimod-treated patients and controls. Overall, in
clinical studies fingolimod was well tolerated and had a
favorable safety profile. In follow-up studies with contin-
uous fingolimod, treatment showed sustained efficacy while
being well tolerated.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demye-
linating disease of the central nervous system (CNS)
accompanied by substantial neurodegenerative processes.
The heterogeneous clinical disease course, radiologic, and
pathologic findings hamper a full understanding of the
complex interrelationship of inflammatory response and
tissue damage in different subgroups and phases of the
disease [1, 2]. In recent years however, the immunologic
mechanisms underlying the disease have been better
understood and, based on this, new therapeutic approaches
have been developed. This widened the therapeutic options
substantially. Oral immunomodulators might broaden the
therapeutic armamentarium and potentially provide effective,
more convenient, and more selective treatment options of the
inflammatory but also the neurodegenerative components of
the disease. Among them, oral fingolimod is the first member
of a new class of immunomodulators that targets sphingosine
receptors. The drug has shown clinical and MRI efficacy in
clinical phase 2 and 3 trials of relapsing MS and is now
registered for the treatment of relapsing remitting MS in many
countries [3••, 4••, 5••].
Mechanism of Action
Immunologic Effects
Fingolimod (FTY720) is a sphingosine analogue and is
phosphorylated by sphingosine kinase 1 and 2 as its natural
counterpart [6, 7]. Sphingosine-1 phosphate (S1P) binds to
G-protein-coupled S1P receptors. To date, five subtypes of
S1P receptors (S1P1–5) have been identified (Table 1) [8]. T
cells, B cells, and natural killer (NK) cells mainly express
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S1P1 and to a smaller extent S1P3–5 (T cells), S1P3 (B
cells), and S1P5 NK cells [9]. In the CNS, astrocytes
express S1P1–3 and S1P5 [10], microglia cells express
S1P1–3 and S1P5 [11, 12], and mature oligodendrocytes
express S1P1, S1P3, and S1P5 [9, 13, 14]. In immune cells
that recirculate to secondary lymphoid organs (SLOs) such
as lymph nodes, binding of S1P to S1P1 mediates egress
from SLOs [15]. Phosphorylated fingolimod binds as an
analogue of S1P to the S1P receptors S1P1, S1P3, S1P4, and
S1P5. Binding of phosphorylated fingolimod to S1P1 on
lymphocytes results in internalization and degradation of
the receptor [16]. As a result, S1P1-mediated egress of
lymphocytes from SLOs to the periphery is blocked [17, 18].
Accordingly, inhibition of lymphocyte egress from SLOs by
fingolimod pertains most likely also autoreactive T cells that
mediate inflammation in MS lesions [19]. In fingolimod-
treated patients withMS the percentages of CD4+ andCD8+ T
lymphocytes are reduced [20]. Among them naïve T cells and
central memory T cells (TCM) that recirculate to SLOs on a
regular basis are predominantly reduced, whereas effector
memory T cells (TEM) that do not recirculate on a regular
basis to SLOs account for the majority of blood T
lymphocytes in fingolimod-treated MS patients.
In recent years a T-cell subset characterized by the
production of interleukin (IL)-17 has been demonstrated to
play a central role in various models of human autoimmune
such disease as experimental autoimmune encephalomyelitis,
the animal model of MS [21–23]. In patients with MS the
number of IL-17A mRNA-positive Th17 cells is elevated in
peripheral blood and Th17 cells are enriched in the
cerebrospinal fluid of patients with MS [22–24]. In MS
lesions, Th17 cells are detected in high numbers and have an
enhanced capacity to kill human neuronal cells when
compared with control T cells [25, 26]. Blood CD4+ T cells
with phenotypic and functional characteristics of Th17 cells
are contained predominantly within the TCM subset, but are
not found in TEM cells [27]. As a consequence, reduction of
TCM by fingolimod treatment coincides with a major
reduction of CD4+ Th17-like cells in blood. This finding
was supported by the reduced expression of the Th17-
specific transcription factor RORC2 and of barely detectable
secretion of IL-17 by T cells of fingolimod-treated patients.
Together these findings suggest that TEM and TEMRA cells
are the predominant T-cell subtypes that remain in the
peripheral blood of patients treated with fingolimod, and
that egress from SLOs of naïve Tcells, TCM, and Th17 cells
are inhibited by fingolimod.
Besides T cells, numerous immune cells such as B cells,
dendritic cells, and macrophages express sphingosine
receptors [28]. Results from human studies and animal
models indicate that functional antagonism of S1P inhibits
also their egress from SLOs or migration into peripheral
tissue [29–31], but this has not been reported with regard to
fingolimod therapy in patients with MS. It was shown that
the production of the proinflammatory cytokine IL-12p70
by blood-derived myeloid cells was inhibited [32]. In
dendritic cells the production of the anti-inflammatory
cytokine IL-10 was reduced, indicating together with the
aforementioned reduction of IL-12 secretion additive anti-
inflammatory effects.
CNS Effects of Fingolimod
In addition to its effects on lymphocytes, fingolimod has
been reported to exert direct effects on CNS cells involved
in the pathogenesis of MS such as astrocytes, oligoden-
drocytes, and microglia. Fingolimod and the phosphorylated
active form (fingolimod-P) cross the blood–brain barrier and
drug levels are found in steady-state conditions in higher
concentrations in the brain parenchyma than in blood in
treated animals [33]. In the CNS fingolimod colocalizes with
myelin, presumably as a result of its lipophilic nature [34,
35]. In CNS tissue from patients with MS, mRNA levels of
S1P receptors are upregulated in cells adjacent to MS
lesions, and a strong increase in S1P1&3 expression on
reactive astrocytes is found in active and chronic inactive
MS lesions [36]. In rodents, progenitor and mature oligoden-
drocytes express S1P1 and S1P5 in vivo and in vitro [13].
Fingolimod induces modulation of S1P receptors on
human oligodendrocyte progenitor cells (OPCs) and regu-
lates differentiation of OPCs into oligodendrocytes [37–39].
In a system of lysolecithin-induced demyelination in
organotypic cerebellar slice cultures fingolimod enhanced
remyelination and process extension by OPCs and mature
oligodendrocytes [40]. These effects were mediated primarily
through S1P3 and S1P5. Fingolimod further rescued human
mature myelin-producing oligodendrocytes from serum and
glucose deprivation–induced apoptosis [41]. In astrocytes
S1P and fingolimod augmented extracellular signal–regulated
kinase (ERK), which mediates signaling for cell proliferation
S1P1 S1P2 S1P3 S1P4 S1P5
Lymphocytes Astrocytes Lymphocytes Lymphocytes Lymphocytes
Astrocytes Microglia Astrocytes Astrocytes
Microglia Microglia Microglia
Oligodendrocytes Oligodendrocytes Oligodendrocytes
Table 1 Expression of S1P
subtypes in lymphocytes, glial
cell subs, and neurons
S1P sphingosine 1-phosphate.
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[42]. In the presence of tumor necrosis factor-α, S1P1 and
S1P3 are upregulated in primary cultures of human astrocytes
and fingolimod reduced the secretion of proinflammatory
cytokines in these cells. This indicates regulation of S1P
expression in astrocytes under proinflammatory conditions
and direct anti-inflammatory effects of fingolimod in
astrocytes [36]. In contrast to human astrocytes, fingolimod
reduces ERK phosphorylation in human microglia cells [32].
Taken together, these findings implicate that fingolimod
treatment, in addition to its effects on the composition of
peripheral blood T-cell subsets, also has direct effects on
oligodendrocytes, astrocytes, and microglia. These direct or
indirect neuroprotective effects could serve as an explana-
tion for the reduced loss of brain volume observed in
fingolimod-treated patients [4••].
Clinical Outcomes
Clinical efficacy and safety of fingolimod in relapsing MS
have been evaluated in one phase 2 and two phase 3 studies
and resulted in approval of the drug for relapsing MS in
2010 by the US Food and Drug Administration (FDA). In
the phase 2 study, 281 patients with active relapsing MS—
defined by at least two relapses during the previous 2 years
or one relapse in the previous year or one gadolinium-
enhancing (Gd+) lesion on MRI—and an Expanded
Disability Status Scale (EDSS) of 0 to 6.0 were equally
randomized to receive oral fingolimod 1.25 mg or 5 mg or
placebo once daily [3••]. The primary end point was the
cumulative number of Gd+ lesions per patient in monthly
MRIs. Both dosages of fingolimod reduced the total number
of Gd+ lesions compared with placebo significantly. Also,
several secondary end points were met: 1) The proportion of
patients who were free from Gd+ lesions was greater in both
fingolimod groups. 2) The annualized relapse rate (ARR) was
reduced by 53% to 55% in fingolimod-treated patients. 3)
Significantly more fingolimod-treated patients (86%)
remained relapse-free when compared with the placebo group
(66%). After completion of the core study patients were
offered to enter an open-label, active-drug extension study in
which the previously placebo-treated patients were randomized
to fingolimod. Also, this group showed a significant decrease in
the number of Gd+ lesions and the ARR after initiation of
treatment with fingolimod.
In an open-label extension study following the phase 2
core study the reduced number of Gd+ lesions, which was
observed during the first 6 months of fingolimod treatment
in the core study, was sustained after 24 and 36 months and
the majority of patients remained free from Gd+ lesions or
new T2 lesions [43, 44]. In line with this most patients
remained free from relapses and EDSS scores were stable.
During months 15 to 24, patients receiving fingolimod
5 mg were switched to fingolimod 1.25 mg, which was
related to fewer side effects while being comparably
efficacious. MRI and clinical outcomes demonstrated a
continuous beneficial effect of fingolimod treatment and
confirmed the 24-month findings of the extension study.
The results of the phase 2 study were confirmed in two
phase 3 studies. The FREEDOMS (FTY720 Research
Evaluation Effects of Daily Oral therapy in MS) study was
placebo-controlled; the TRANSFORMS (Trial Assessing
Injectable Interferon Versus FTY720 Oral in RRMS) study
compared fingolimod to the established MS therapeutic
interferon-β1a (IFN-β1a; intramuscular once weekly).
In the FREEDOMS study patients were randomized to
receive oral fingolimod 0.5 mg, fingolimod 1.25 mg, or
placebo once daily over 24 months [4••]. A total of 1272
patients with relapsing MS with an EDSS between 0 and 5.5
who had one relapse during the last year or two relapses
during the previous 2 years were recruited for the study.
Mean age of patients was 37 years. Approximately 60%
were treatment-naïve, mean disease duration was 8 years,
and the mean EDSS was 2.4. Compared with placebo,
treatment with fingolimod reduced the ARR significantly
(fingolimod 0.5 mg: 0.18; fingolimod 1.25 mg: 0.16; placebo
0.4), which corresponds to a relative risk reduction of 54% to
60%. Also, the time to confirmed disability progression after
3 and 6 months was prolonged significantly in both
fingolimod groups. In addition, several secondary end points
were favorable for fingolimod: Fingolimod treatment decreased
the number of Gd+ lesions and the number of new or enlarged
T2 lesions significantly. Increase of the volume of T1-
hypointense lesions as a marker for tissue damage and
whole-brain atrophy were also reduced by fingolimod.
In the TRANSFORMS study patients were randomized
in a double-dummy design to oral fingolimod 0.5 mg,
fingolimod 1.25 mg, or IFN-β1a intramuscularly once
weekly [5••]. A total of 1292 patients with relapsing MS
with an EDSS between 0 and 5.5 who had one relapse
during the last year or two relapses during the previous
2 years were recruited for the study. Mean age was 36 years,
and the majority of patients (~56%) had previous treatment
for MS, mostly IFN-β or glatiramer acetate. Average
disease duration was 7.4 years, and the patients had a mean
EDSS of 2.2. In both fingolimod groups a significant
reduction of the ARR compared with IFN-β1a was noted
(fingolimod 0.5 mg: 0.16; fingolimod 1.25 mg: 0.2; IFN-
β1a: 0.33). Corresponding to this the proportion of relapse-
free patients was significantly higher in fingolimod-treated
patients (fingolimod 0.5 mg: 82.6%; fingolimod 1.25 mg:
79.8%; IFN-β1a: 69.3%). Patients in the fingolimod groups
also had less Gd+ lesions, a reduced number of new or
enlarged T2 lesions, and less brain atrophy.
In an extension of the TRANSFORMS study patients
who were treated with IFN-β1a in the core study were
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randomly assigned to receive 0.5 mg or 1.25 mg of
fingolimod, whereas the initially fingolimod-treated patients
continued their treatment [45••]. Primary end points were the
ARR, disability progression, and MRI outcomes. Patients
receiving continuous fingolimod had unchanged benefits in
the ARR. Patients who were switched from IFN-β1a to
fingolimod showed a significant decrease of the ARR. Also,
numbers of new or newly enlarging T2 lesions, Gd+ lesions,
and the rate of brain volume decline were reduced.
Compared with patients who had switched from IFN-β1a
therapy to fingolimod, continuously fingolimod-treated
patients had a significantly lower ARR and reduced
inflammatory activity in brain MRI. Side effects shifted in
patients who were switched to fingolimod to a profile that is
known from other studies in fingolimod-treated patients with
MS.
In all clinical studies fingolimodwas well tolerated and had
a favorable safety profile. Apart from the fingolimod 5-mg
group, in the phase 2 study the frequency of adverse events in
fingolimod-treated patients was comparable with controls.
Therefore, patients treated with fingolimod 5 mg were
switched to fingolimod 1.25 mg during months 15 to 24 of
the phase 2 extension study [44]. The vast majority of adverse
events were mild to moderate in all study groups. The most
common serious adverse events in fingolimod-treated
patients were transient bradycardia and atrioventricular block
related to the first dose of the medication, MS relapses, and
basal cell carcinoma. Macular edema occurred in 1% of the
patients in the 1.25-mg group and 0.5% of the 0.5-mg group
and resolved in most patients after discontinuation of
fingolimod therapy. Other adverse events occurred in less
than 1% of the study populations.
In all clinical studies the frequency of overall infections
was comparable in fingolimod-treated patients and controls.
Nasopharyngitis was the most frequent infection with no
differences between patients treated with fingolimod 0.5 mg
or 1.25 mg and controls. In the placebo-controlled phase 3
study, lower respiratory tract infections (including bronchitis
and pneumonia) were more frequent in patients treated with
fingolimod. Two deaths related to herpes virus infections
occurred during the TRANSFORMS study. One patient
developed primary disseminated varicella zoster infection
after exposure to a child with chicken pox while under
corticosteroid treatment. One patient developed lethal herpes
simplex encephalitis, primarily treated with intravenous
corticosteroids for suspected relapse of MS.
Besides lymphopenia, elevated alanine aminotransferase
(ALAT) levels were common abnormal laboratory findings
in all study groups, but were more frequent in patients
treated with fingolimod. Up to 12.5% of patients had ALAT
levels three times the upper limit of the normal range or
more. In all patients liver enzyme abnormalities returned to
normal after drug discontinuation.
After completing the core phase 3 studies, patients were
offered to enter into open-label, uncontrolled active-drug
extension phases. Patients previously treated with placebo
or IFN-β1a were switched to fingolimod 0.5 mg or
1.25 mg, whereas the others continue their assigned
dosages.
Currently, all patients from the phase 2 and the two
phase 3 studies are monitored in a single extension study.
Herein all patients were switched to fingolimod 0.5 mg.
Patients are scheduled every third month for clinical and
laboratory assessments. The study aims at compiling
additional data on the long-term safety and tolerability of
fingolimod therapy.
Future Directions
After introduction of fingolimod for the treatment of
relapsing MS, a phase 4 clinical program aims to assess
tolerability and safety of the drug when used in patients
under non-study condition. In addition to the follow-up
studies of the clinical studies, this will also help to assess
long-term tolerability of fingolimod. In autumn 2011,
results of two phase 3b studies of fingolimod in MS will
be available. One study assessed the effect of fingolimod
treatment on the induction of an antigen-specific immune
response to influenza vaccination as a model for a newly
induced immune response and on the induction of a recall
immune response to tetanus booster vaccination. In a
second phase 3b study, tolerability of initiation of fingolimod
treatment without the currently required 6-hour observation
period for cardiovascular monitoring after the first dose was
assessed. Because the mode of action may also have direct
neuroprotective effects, fingolimod is being evaluated in a
phase 3 study in patients with primary progressive MS.
Ongoing phase 2 studies are evaluating the clinical efficacy
and safety of new compounds that are more specific for certain
S1P receptors with the aim to further improve the efficacy/
safety profile.
Conclusions
Oral fingolimod is the first member of the new class of
S1P1 modulators and has been approved by the FDA and
European Medicines Agency for the treatment of relapsing
MS. Two large phase 3 clinical trials showed a superior
efficacy of fingolimod compared to both placebo and IFN-
β1a intramuscularly. Fingolimod was well tolerated and
safe. The overall incidence of infections, including severe
and serious infections, was comparable between control
groups and those receiving fingolimod 0.5 mg. However, a
slightly increased incidence of lower respiratory tract and
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lung infections (mainly bronchitis) was seen in fingolimod-
treated patients. Follow-up studies will continue to assess
the long-term tolerability and safety of fingolimod. The
study addressing the effects of fingolimod in primary
progressive MS will potentially help to better characterize
the neuroprotective effect of fingolimod.
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